Phase II trial of 4'-epi-doxorubicin in advanced colorectal carcinoma: a Northern California Oncology Group study.
D000328:Adult; D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010976:Platelet Count; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D015251:Epirubicin; D004317:Doxorubicin